US4948587A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ultrasound enhancement of transbuccal drug delivery
Assignee: Massachusetts Institute of Technology
•
Filing: 1988-08-18
•
Granted: 1990-08-14
•
Expires: 2008-08-18
Abstract
Abstract A method using ultrasound for enhancing and controlling transbuccal permeation of a molecule, including drugs, antigens, vitamins, inorganic and organic compounds, and various combinations of these substances, through the buccal membranes and into the circulatory system. The frequency and intensity of ultrasonic energy which is applied, and the length of time of exposure are determined according to the location and nature of the buccal membrane and the substance to be infused. Levels of the infused molecules in the blood and urine measured over a period of time are initially used to determine under what conditions optimum transfer occurs. In a variation of the method, whereby ultrasound is applied directly to the compound and site where the compound is to be infused through the buccal membranes, the compound can be placed within a delivery device. In one variation, the ultrasound can control release both by direct interaction with the compound and membrane but also with the delivery device. In another variation, the delivery device helps to modulate release and infusion rate. The compound can also be administered in combination with a chemical agent which alters permeability of the buccal membrane, thereby aiding infusion of the compound into the circulatory system.
Inventors
- 👤 Joseph Kost
- 👤 Robert S. Langer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:03
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0047; A61K9/00; A61K9/0002; A61K9/0009; A61M; A61M37/00; A61M37/0092
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
101 words
A method for enhancing and controlling transbuccal infusion of molecules comprising: (a) selecting the molecules to be infused through the buccal membranes; (b) applying said molecules to the buccal membrane; (c) applying ultrasound to said molecules at a frequency of between 20 kHz and 10 MHz and an intensity of between 0 and 4 W/cm 2 ; and (d) varying the frequency and intensity over time to infuse said molecules through the transbuccal membranes at an optimal rate into the circulatory system without delay or damaging the buccal membranes, wherein the optimal rate is determined by measurements of a physiological fluid.
Claim 2
Independent Claim
101 words
A method for enhancing and controlling transbuccal infusion of molecules comprising: (a) selecting the molecules to be infused through the buccal membranes; (b) applying said molecules to the buccal membrane; (c) applying ultrasound to said molecules at a frequency of between 20 kHz and 10 MHz and an intensity of between 0 and 4 W/cm 2 ; and (d) varying the frequency and intensity over time to infuse said molecules through the transbuccal membranes at an optimal rate into the circulatory system without delay or damaging the buccal membranes, wherein the optimal rate is determined by measurements of a physiological fluid.
Claim 3
Dependent Claim
25 words
The method of claim 1 further comprising measuring the concentration of said molecules in a physiological fluid during or immediately after administration of the ultrasound.
Claim 4
Dependent Claim
59 words
The method of claim 1 further comprising measuring the concentrations of said molecule in the physiological fluid over time, determining the rate of transbuccal transfer for said molecules at specific frequencies, intensities and times of ultrasound application, wherein the molecules are subsequently infused using ultrasound at the frequency, intensity, and time of application determined to yield a specific concentration.
Claim 5
Dependent Claim
29 words
The method of claim 1 wherein the ultrasound frequency is applied at between 0.5 MHz and 1.5 MHz and an intensity of between 2 and 4 W/cm 2 .
Claim 6
Dependent Claim
15 words
The method of claim 1 wherein the ultrasound is applied for less than ten minutes.
Claim 7
Dependent Claim
10 words
The method of claim 1 wherein the ultrasound is pulsed.
Claim 8
Dependent Claim
10 words
The method of claim 1 wherein the ultrasound is continuous.
Claim 9
Dependent Claim
41 words
The method of claim 1 wherein the molecule is selected from the group of molecules consisting of proteins, drugs, antigens, vitamins, inorganic compounds, organic compounds, and combinations thereof, wherein said molecule has a biological effect when infused into the circulatory system.
Claim 10
Dependent Claim
46 words
The method of claim 1 further comprising measuring the temperature of the membrane where the ultrasound is applied and applying the ultrasound at a frequency and intensity over a period of time which does not cause an increase in skin temperature of more than 2° C.
Claim 11
Dependent Claim
68 words
A combination of molecules for transbuccal infusion and an ultrasound emitter adapted to enhance such infusion, the ultrasound emitter comprising control circuits adapted to deliver ultrasound at a frequency of between 20 kHz and 10 MHz and at an intensity of between 0 and 4 W/cm 2 for a period such that the molecules are infused through the buccal membrane at a controlled rate without damaging the membrane.
Claim 12
Dependent Claim
68 words
A combination of molecules for transbuccal infusion and an ultrasound emitter adapted to enhance such infusion, the ultrasound emitter comprising control circuits adapted to deliver ultrasound at a frequency of between 20 kHz and 10 MHz and at an intensity of between 0 and 4 W/cm 2 for a period such that the molecules are infused through the buccal membrane at a controlled rate without damaging the membrane.
Claim 13
Dependent Claim
20 words
The combination of claim 10 further comprising means to measure the temperature of the buccal membrane at the infusion site.
Claim 14
Dependent Claim
54 words
A composition for controlled delivery through the buccal membranes comprising molecules in a pharmaceutically effective concentration in a medium suitable for administration through the buccal membranes when ultrasound is applied to said molecules at a frequency of between 20 kHz and 10 MHz and an intensity of between 0 and 4 W/cm 2 .
Claim 15
Dependent Claim
54 words
A composition for controlled delivery through the buccal membranes comprising molecules in a pharmaceutically effective concentration in a medium suitable for administration through the buccal membranes when ultrasound is applied to said molecules at a frequency of between 20 kHz and 10 MHz and an intensity of between 0 and 4 W/cm 2 .
Claim 16
Dependent Claim
26 words
The composition of claim 12 wherein said medium is a polymeric matrix and said molecules can diffuse out of said polymeric matrix into the buccal membranes.
Claim 17
Dependent Claim
16 words
The composition of claim 12 wherein said medium dissolves in the environment of the buccal membranes.
Claim 18
Dependent Claim
39 words
The composition of claim 12 wherein said medium is a polymeric matrix and said polymeric matrix releases said molecules from said matrix in a controlled manner over a specific time period when said matrix is exposed to ultrasonic energy.
Claim 19
Dependent Claim
36 words
The composition of claim 12 wherein said medium is a polymeric matrix formed of polymer selected from the group consisting of polyanhydrides, polylactic acid, polyglycolic acid, ethylene vinyl acetate copolymers, polypropylene, polyethylene, and other biocompatible polymers.
Claim 20
Dependent Claim
17 words
The composition of claim 12 further comprising chemical compounds which alter the permeability of the buccal membranes.
Claim 21
Dependent Claim
32 words
The composition of claim 12 further comprising a medium having an absorbtion coefficient similar to that of water which facilitates transfer of the ultrasound to the infusion site on the buccal membranes.
References Cited (Backward Citations)
US4127125A
Cited
US4309989A
Cited
US4176664A
Cited
US4280494A
Cited
US4372296A
Cited
US4563184A
Cited
US4780212A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-13 | 1994-02-12 | 1994-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-13 | 1998-02-12 | 1998-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-13 | 2002-02-12 | 2002-08-14 | $7700.00 | Window Closed / Lapsed |